No results for ‘’
Krebs Biochemicals & Industries Ltd
₹65.58
(1.97%)
Tue, 23 Jun 2026, 03:28 am
Health Technology
Pharmaceuticals: Major
24.5KKrebs Biochemicals & Industries PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 0.56 | 0.54 | 0.34 | 0.32 | 0.66 | 0.76 | 0.92 | 1.68 | 0 | 10.87 | 127.09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to sales ratio | 1.74 | 0.89 | 0.62 | 0.30 | 0.69 | 0.43 | 0.29 | 0.92 | 0 | 109.41 | 68.11 | 6.89 | 4.13 | 4.55 | 3.31 | 5.11 | 2.31 | 2.61 | 3.32 |
| Price to cash flow ratio | 3.49 | 0 | 0 | 0 | 0 | 14.41 | 2.08 | 2.76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterprise value | 154Cr | 128Cr | 109Cr | 97.1Cr | 117Cr | 116Cr | 107Cr | 100Cr | 139Cr | 167Cr | 185Cr | 281Cr | 229Cr | 213Cr | 285Cr | 452Cr | 305Cr | 325Cr | 356Cr |
| Enterprise value to EBITDA ratio | 187.24 | 10.71 | 11.75 | 0 | 28.09 | 564.14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 1.19 | 0.95 | 0.86 | 1.60 | 1.89 | 2.12 | 3.78 | 11.66 | 0 | 2.42 | 43.90 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | -8.54 | -11.16 | -59.72 | -11.60 | -15.44 | -55.06 | 0 | -594.53 | -288.01 | -234.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Krebs Biochemicals & Industries Ltd Price to Book Ratio
The Krebs Biochemicals & Industries Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Krebs Biochemicals & Industries Ltd's valuation, profitability, and overall financial performance. Tracking the Krebs Biochemicals & Industries Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Krebs Biochemicals & Industries Ltd (NSE: KREBSBIO, BSE: 524518) is currently trading at ₹65.58, with a market capitalization of ₹142.24Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Krebs Biochemicals & Industries Ltd Price to Book Ratio is essential for fundamental analysis.
Krebs Biochemicals & Industries Ltd Price to Book Ratio Current Value
The current Krebs Biochemicals & Industries Ltd Price to Book Ratio stands at 0.
The Krebs Biochemicals & Industries Ltd Price to Book Ratio remains stable, indicating consistent financial performance.
Krebs Biochemicals & Industries Ltd Price to Book Ratio Historical Trend
The Krebs Biochemicals & Industries Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0
The decline in Krebs Biochemicals & Industries Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What Krebs Biochemicals & Industries Ltd Price to Book Ratio Indicates for Investors
The Krebs Biochemicals & Industries Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Krebs Biochemicals & Industries Ltd Price to Book Ratio Analysis Summary
The Krebs Biochemicals & Industries Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Krebs Biochemicals & Industries Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Krebs Biochemicals & Industries Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.